Clinical and immunological responses after CD30-specific chimeric antigen receptor–redirected lymphocytes

BACKGROUND. Targeting CD30 with monoclonal antibodies in Hodgkin lymphoma (HL) and anaplastic large cell lymphoma (ALCL) has had profound clinical success. However, adverse events, mainly mediated by the toxin component of the conjugated antibodies, cause treatment discontinuation in many patients....

Full description

Saved in:
Bibliographic Details
Published in:J Clin Invest
Main Authors: Ramos, Carlos A., Ballard, Brandon, Zhang, Huimin, Dakhova, Olga, Gee, Adrian P., Mei, Zhuyong, Bilgi, Mrinalini, Wu, Meng-Fen, Liu, Hao, Grilley, Bambi, Bollard, Catherine M., Chang, Bill H., Rooney, Cliona M., Brenner, Malcolm K., Heslop, Helen E., Dotti, Gianpietro, Savoldo, Barbara
Format: Artigo
Language:Inglês
Published: American Society for Clinical Investigation 2017
Subjects:
Clinical Medicine
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC5669573/
https://ncbi.nlm.nih.gov/pubmed/28805662
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI94306
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items